Data gathered: January 15
AI Stock Analysis - Bio Path Holdings (BPTH)
Analysis generated August 14, 2024. Powered by Chat GPT.
Bio-Path Holdings, Inc. is a clinical-stage biotechnology company that develops targeted oncology therapies. The company's lead product candidate, Prexigebersen, is in clinical trials for multiple indications. Bio-Path aims to revolutionize cancer treatment by delivering antisense RNAi therapeutics for patients with high unmet medical needs. Their innovative platform and strategic approach in the biotech niche make Bio-Path Holdings a potentially influential player in the medical field.
Stock Alerts - Bio Path Holdings (BPTH)
 |
Bio Path Holdings | January 14 Price is down by -5.6% in the last 24h. |
|
Bio Path Holdings | January 13 Price is down by -7.4% in the last 24h. |
|
Bio Path Holdings | January 10 Price is down by -7.5% in the last 24h. |
|
Bio Path Holdings | January 8 Price is down by -7.8% in the last 24h. |
Alternative Data for Bio Path Holdings
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 41 | Sign up | Sign up | Sign up |
| Webpage traffic | 2,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 6 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 18,798 | Sign up | Sign up | Sign up |
| Twitter Followers | 101 | Sign up | Sign up | Sign up |
| Twitter Mentions | 21 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Bio Path Holdings
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States.
| Price | $0.84 |
| Target Price | Sign up |
| Volume | 494,710 |
| Market Cap | $4.1M |
| Year Range | $0.61 - $3.23 |
| Dividend Yield | 0% |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
 |
Bio-Path (NASDAQ:BPTH) Now Covered by StockNews.comJanuary 12 - ETF Daily News |
|
StockNews.com Initiates Coverage on Bio-Path (NASDAQ:BPTH)January 3 - ETF Daily News |
 |
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q3 24December 13 - Yahoo |
 |
Bio-Path (NASDAQ:BPTH) Coverage Initiated by Analysts at StockNews.comDecember 9 - ETF Daily News |
 |
Bio-Path Holdings Inc (BPTH) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial ...November 20 - Yahoo |
|
Bio-Path (NASDAQ:BPTH) Earns Sell Rating from Analysts at StockNews.comNovember 18 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 1.3M | -1.3M | -2.1M | 0 | -0.700 |
| Q2 '24 | 0 | 1.2M | -1.2M | -1.9M | -3M | -1.160 |
| Q1 '24 | 0 | 1.4M | -1.4M | -3.2M | -3.6M | -4.880 |
| Q4 '23 | 270,000 | 760,000 | -760,000 | -3.4M | -3M | -7.050 |
| Q3 '23 | 0 | 980,000 | -980,000 | -3.2M | -3.3M | -0.320 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
Read more about Bio Path Holdings (BPTH) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Bio Path Holdings?
The Market Cap of Bio Path Holdings is $4.1M.
What is the current stock price of Bio Path Holdings?
Currently, the price of one share of Bio Path Holdings stock is $0.84.
How can I analyze the BPTH stock price chart for investment decisions?
The BPTH stock price chart above provides a comprehensive visual representation of Bio Path Holdings' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Bio Path Holdings shares. Our platform offers an up-to-date BPTH stock price chart, along with technical data analysis and alternative data insights.
Does BPTH offer dividends to its shareholders?
As of our latest update, Bio Path Holdings (BPTH) does not offer dividends to its shareholders. Investors interested in Bio Path Holdings should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Bio Path Holdings?
Some of the similar stocks of Bio Path Holdings are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.